NEW YORK, May 6, 2011 /PRNewswire-Asia-FirstCall/ --
American Oriental Bioengineering, Inc. (NYSE: AOB), ("the Company"
or "AOBO"), a pharmaceutical company dedicated to improving health
through the development, manufacture and commercialization of a
broad range of prescription and over the counter ("OTC") products,
today announced that it plans to release first quarter 2011
financial results on Monday, May 9,
2011, after the market closes.
The Company will hold a conference call at 8:00 am ET on Tuesday, May
10, 2011, to discuss its results. Listeners may access
the call by dialing 1-877-299-4454 or 1-617-597-5447 for
international callers, access code: 91826695. A webcast will
also be available through AOB's website at www.bioaobo.com.
A replay of the call will be available through May 17, 2011. Listeners may access the
replay by dialing 1-888-286-8010 or 1-617-801-6888 for
international callers, access code: 86841058.
About American Oriental Bioengineering, Inc.
American Oriental Bioengineering, Inc. is a pharmaceutical
company dedicated to improving health through the development,
manufacture and commercialization of a broad range of prescription
and over the counter products.
Safe Harbor Statement
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks
and uncertainties that may cause actual results to differ
materially from those set forth in these statements. The
economic, competitive, governmental, technological and other
factors identified in the Company's filings with the Securities and
Exchange Commission, may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation
to publicly update or revise any forward-looking statements,
whether because of new information, future events, or
otherwise.
Contact:
ICR, LLC
Christine Duan or Ashley Ammon
203-682-8200
SOURCE American Oriental Bioengineering, Inc.